Author | Year | Intervention | No Osteo Patients | No Ewing Patients | Phase | Outcome |
---|---|---|---|---|---|---|
Daw et al, J Clin Oncol, 23 (25): 6172-80 [40] | 2005 | Gefitinib | 6 | 3 | I | 1 (4%) PR, 4 (16%) SD |
Maki et al, Cancer, 103 (7): 1431-8 [41] | 2005 | Bortezomib | 1 | 2 | II | 1 (4%) OR |
Villablanca et al, J Clin Oncol, 24 (21): 3423-30 [42] | 2006 | Fenretinide | 2 | 5 | I | 1 (2%) CR, 13 (24%) SD |
Biron et al, ASCO abstract | 2007 | Gimatecan | 0 | Not mentioned | II | 3 (8%) SD |
Bagatell et al, Clin Cancer Res, 13 (6): 1783-8 [43] | 2007 | Tanespimycin | 6 | 2 | I | 0% OR |
Jimeno et al, Pediatr Blood Cancer, 49 (3): 352-7 [44] | 2007 | Gefitinib | 3 | 1 | I | 1 (7%) PR, 3 (20%) SD |
Kramer et al, J Clin Oncol, 25 (34): 5465-70 [45] | 2007 | Monoclonal antibody(131-I-3F8) | 0 | 2 | I | 3 (23%) ClR |
Bond et al, Pediatr Blood Cancer, 50 (2): 254-8 [46] | 2008 | Imatinib mesylate | 10 | 24 | II | 1 (1%) PR |
Chao et al, ASCO abstract | 2008 | Imatinib mesylate | 0 | 7 | II | 1 (14%) PR |
Fox et al, Clin Cancer Res, 14 (4): 1111-5 [47] | 2008 | Tubulin Inhibitor (ABT-751) | 3 | 3 | I | 0% OR |
Jakacki et al, J Clin Oncol, 26 (30): 4921-7 [48] | 2008 | Erlotinib, Temozolomide | 1 | 0 | I | 1 (2%) SD |
Langevin et al, Pediatr Blood Cancer, 50 (3): 577-80 [49] | 2008 | Rebeccamycin | 16 | 14 | II | % OR |
Mita et al, J Clin Oncol, 26 (3): 361-7 [50] | 2008 | Deforolimus | 1 | 1 | I | 4 (13%) PR, 18 (56%) SD |
Olmos et al, ASCO abstract | 2008 | Figitumumab | 0 | 9 | I | 1 (5%) PR, 6 (27%) SD |
Chawla et al, Mol Ther, 17 (9): 1651-7 [51] | 2009 | Rexin-G | 3 | 1 | I/II | 13 (65%) SD |
Chugh et al, J Clin Oncol, 27 (19): 3148-53 [52] | 2009 | Imatinib | 27 | 13 | II | 1 (0.5%) CR, 3 (2%) PR |
Malempati et al, ASCO abstract | 2009 | Cixutumumab | Not mentioned | 10 | I | 1 (4%) PR |
Patel et al, ASCO abstract | 2009 | IGF-1R antibody (R1507) | 43 | 71 | II | Not mentioned |
Widemann et al, J Clin Oncol, 27 (4): 550-6 [53] | 2009 | Ixabepilone | 3 | 2 | I | 4 (21%) SD |
Jacobs et al, Clin Cancer Res, 16 (2): 750-4 [54] | 2010 | Ixabepilone | 11 | 9 | II | 0% OR |
Kurzrock et al, Clin Cancer Res, 16 (8): 2458-65 [55] | 2010 | IGF-1R antibody (R1507) | 0 | 9 | I | 2 (5%) PR, 13 (35%) SD |
Olmos et al, Lancet Oncol, 11: 129-35 [56] | 2010 | Figitumumab | 0 | 16 | I | 1 (3%) CR, 1 (3%) PR, 8 (28%) SD |